Sarepta Therapeutics Inc - SRPT Company Cash Volume

Corporate emblem and logo of Sarepta (SRPT)

Sarepta Therapeutics, Inc. (SRPT) is strengthening its position through strategic partnerships with pharma behemoths, accelerating the release of its drugs. The cash-on-hand metric confirms this trend, where 0.87 records the value of this parameter. However, the risk of therapy approval delays and insurance complexities remain relevant, although a stable staff of top geneticists guarantees the company's technological superiority.

Sarepta Corp - SRPT Company Cash Volume (period 07/04/2022 - 11/21/2026)

Analytical breakdowns and data insights for company Sarepta (SRPT)

- stock value and consensus price forecast:
Fundamental company analysis:SRPT sarepta.com
Brand item of sarepta.com

Developing costly gene therapies for the treatment of muscular dystrophy requires colossal R&D capital expenditures from Sarepta Therapeutics, Inc. (SRPT). Analyzing the cash on hand allows for a real-time assessment of the actual liquidity reserve available to fund innovation, eliminating accounting report lags and demonstrating the company's ability to sustain operations without bankruptcy risk during periods of macroeconomic instability.

Main competitors

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Company Cash on Hand Twist Bioscience Inc (TWST)|Company Cash Volume TXG|Company Liquid Assets Intellia|Stoke - Company Cash on Hand|BLFS: Company Cash and Cash Equivalents|Wave Life Sciences Corp - Company Cash Volume|Maze Therapeutics, Inc. (MAZE) - Company Cash on Hand|Sionna Therapeutics Inc (SION) - Company Cash Funds|Company Cash on Hand Prime Medicine Corp|Company Cash Funds tayshagtx.com|QURE - Company Cash Position|Company Cash on Hand MGTX (MeiraGTx Holdings plc)|REGENXBIO (RGNX) - Company Cash Position|Company Cash Volume SLDB (Solid Biosciences Inc.)|Company Cash Balance OCGN|PacBio Corp - Company Cash Volume|Benitec Biopharma Inc. (BNTC) - Company Cash on Hand|DSGN: Company Cash Volume|Company Cash and Cash Equivalents RCKT|Company Cash on Hand FDMT|Company Cash and Cash Equivalents LXEO (Lexeo Therapeutics)|Company Cash Volume KRRO|Editas Medicine, Inc. - Company Cash and Cash Equivalents|Company Cash Funds Silence Therapeutics Inc. SLN|Company Cash Volume ProQR Therapeutics N.V. PRQR|CDXS: Company Cash on Hand|Company Cash Position Sangamo (SGMO)|NAUT (Nautilus Bio) - Company Cash on Hand|MGX - Company Liquid Assets|DTIL (Precision BioSciences Inc.) - Company Cash Volume|generationbio.com (GBIO) - Company Liquid Assets|Company Cash Funds Boundless Bio Inc (BOLD)|Company Cash Volume Exicure Inc. (XCUR)|Company Cash Funds imunon.com IMNN|Company Cash Volume Phio Pharmaceuticals PHIO|Mustang Bio Inc - Company Cash Volume|Company Cash Reserve transcodetherapeutics.com|BNGO: Company Cash Volume|Company Cash and Cash Equivalents APDN|BLUE (bluebirdbio.com) - Company Cash Volume|Company Cash Reserve ImmunoPrecise Antibodies IPA|Company Cash on Hand OMGA (omegatherapeutics.com)|Company Cash Volume Singular Genomics Systems, Inc. (OMIC)|Company Cash Volume RGLS (Regulus Therapeutics, Inc.)|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume